Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

and AZ/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan). That is down to the company's ADC technology platform, which means that the cytotoxic payload that circulates systemically after ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...

Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...